Stock Detail
$ABT
Healthcare · 15 tracked mentions in the last 90 days across 5 creators.
Valuation and creator stance reflect the last 90 days. The mention feed below shows the latest tracked mentions across all history.
ABT leans undervalued across 3 creators and 5 classified valuation claims, with 4 direct claims carrying most of the signal.
Creator Evidence
Why creators say this
Explicit claim • strong conviction • basis: multiple relative
As you can see the stock's had a terrible last year or so. You know, at the end of 2025 this was trading for like 26 times. Now it's only trading for less than 18 times 17.95 and the long-term multiple is 20.2. So, Abbott is undervalued relative to its long-term multiple.
Explicit claim • strong conviction • basis: multiple relative
Stock down 33% year-to-date, near 52-week low of $82. Forward P/E of 15-16x, dividend yield at 3% (highest in 5 years). Valuation model gives intrinsic price of $117 (28% margin of safety). Wall Street sees $119 price target (42% upside). ... ABBA's much more interesting than Waste Management from a valuation perspective. And my conclusion is this. ABBA's not the cleanest stock in the episode, but it may be one of the more obvious healthcare valuation resets.
Implied claim • strong conviction • basis: multiple relative
Abbott Labs (ABT) is a high-quality Dividend King with a safe payout ratio under 50%, strong dividend growth, and a solid P/E of 15.5, making it a top pick.
Mention History
Latest mentions across all history
Feed